| CASE REPORT |
|
| Year : 2021 | Volume
: 10
| Issue : 1 | Page : 152-155 |
|
|
A rare case of late presentation of dasatinib-induced cardiopulmonary toxicity
Harshit Khurana1, Vijoy Kumar Jha2, Ajay Handa3, Debasish Mahapatra2
1 Department of Clinical Hematology, Medical Division, Command Hospital Air Force, Bengaluru, Karnataka, India
2 Department of Nephrology, Medical Division, Command Hospital Air Force, Bengaluru, Karnataka, India
3 Department of Pulmonology, Medical Division, Command Hospital Air Force, Bengaluru, Karnataka, India
Correspondence Address:
Dr. Vijoy Kumar Jha
Department of Nephrology, Medical Division, Command Hospital Air Force, Bengaluru - 560 007, Karnataka
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ijrc.ijrc_65_20
|
|
|
Tyrosine kinase inhibitors (TKI) (imatinib, dasatinib, and nilotinib) are used for the treatment and long-term control of chronic myeloid leukemia (CML). TKIs rarely cause systemic side effects with atypical presentations, and these must be borne in mind while prescribing these drugs over a prolonged period. Dasatinib-induced cardiopulmonary toxicity should be suspected in patients presenting with new-onset cardiac or pulmonary symptoms, with features of congestive cardiac failure and pulmonary infiltrates. We report a rare presentation of simultaneous occurrence of pleural effusion, interstitial pneumonitis, pulmonary hypertension, and heart failure in a CML patient on dasatinib for >6 years, which was successfully treated with discontinuation of the drug and oral steroids.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
